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Abstract
Inflammation may play a role in breast cancer, but evidence in the general population is
lacking. We investigated the association between serum inflammatory markers (C-reactive
protein (CRP), absolute granulocyte count (AGC) and granulocyte-to-lymphocyte (G/L)
ratio) and breast cancer (BCa) mortality in American women while accounting for adiposity.
From the Third National Health and Nutrition Examination Survey (NHANES III) we selected
all women aged 20+ without any known history of cancer (n = 7,780). Multivariable Cox
regression models were used to assess CRP, AGC and G/L ratio in relation to mortality
from BCa, all cancer, cardiovascular disease and all causes. Stratification analyses by
body mass index (BMI) and waist circumference were performed to investigate the effect of
adiposity on this association. During a mean follow-up of 167 months, 44 women died from
BCa. After adjustments for BMI and waist circumference, only G/L ratio was associated to
risk of BCa death (e.g. HR: 2.35, 95% CI: 1.36–4.06 for the 3rd compared to the 1st tertile,
Ptrend = 0.01). Except for a borderline interaction between CRP categories and obesity by
BMI, no statistically significant interaction between markers and categories of BMI or waist
circumference was observed. All three markers were associated with mortality from cardio-
vascular disease and all causes. Our findings support a role of inflammation in BCa mortal-
ity which may involve mechanisms apart from obesity, and potential usefulness of GLR as a
marker in assessing inflammation and cancer.
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Introduction
Chronic inflammation is thought to play a role in development and progression of cancer [1].
It may promote early tumourigenesis via pro-inflammatory cytokines and reactive oxygen spe-
cies. In breast cancer (BCa) it is also suggested that inflammation activates the NF-κB signal-
ling pathway, which may lead to development of more aggressive tumour subtypes and BCa
progression through crosstalk with the oestrogen receptor [2].
C-reactive protein (CRP) is probably the most widely investigated marker of inflammation
in the context of cancer detection and prognosis. CRP >10 mg/L is generally accepted as an
indication of acute inflammation, while lower values have been found in low-grade chronic
inflammation [3]. Higher levels of post-diagnosis CRP have been linked with worse survival
in various malignancies, including BCa [4–6], suggesting the importance of inflammation in
cancer progression. However, a consistent association between this marker and cancer risk
has only been demonstrated for lung cancer and colorectal cancer [7,8]. For BCa, a meta-anal-
ysis including over 190,000 participants showed no risk difference in BCa incidence by CRP
levels [9]. Furthermore, although it is thought that obesity may underlie the link between
inflammation and breast cancer, the effect of obesity in this association is not well-defined
[10,11].
Blood neutrophils, often measured as the absolute neutrophil count (ANC), are another
inflammatory marker related to cancer prognosis [12]. Their prognostic value was however
found to be limited in studies with long-term follow-up for cancer progression [13]. More
recently, a ratio of neutrophil to lymphocyte counts in blood (neutrophil-to-lymphocyte ratio;
NLR) was found as a predictor of both short- and long-term mortality in BCa patients, with
higher values being associated with shorter survival [14,15]. Although total white blood count
(WBC) is routinely used as an indicator of inflammation in clinic, the usefulness of these WBC
components in risk prediction of BCa has not yet been investigated.
Using data from the Third National Health and Nutrition Examination Survey (NHANES
III), the current study aims to investigate the link of CRP and NLR with BCa-specific death
while accounting for adiposity. Granulocytes, which majorly consist of neutrophils [16], were
used as a surrogate for neutrophils as the latter were only available in a small number of partici-
pants in the survey.
Methods
Study population
The National Center for Health Statistics (NCHS) conducted NHANES III between 1988 and
1994 and designed it as a multistage stratified, clustered probability sample of the US civilian
non-institutionalized population who was at least two months old. All subjects participated
in an interview conducted at home and an extensive physical examination, which included a
blood sample taken in a mobile examination center [17]. Despite a cross-sectional design,
the NHANES III dataset was linked with the National Death Index (NDI) maintained by
NCHS through December 31, 2006 [18], allowing the use of the dataset as a prospective
cohort. From this population, we included a total of 7,780 females aged 20 and over with
baseline measurements of serum CRP, differential WBC, and eligible mortality follow-up
information. No participants reported a history of cancer at baseline. The protocols for the
conduct of NHANES III were approved by the Institutional Review Board of the NCHS, Cen-
ters for Disease Control and Prevention. Written informed consent was obtained from all
participants.
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Exposure measurements
CRP was measured with an automated Behring Nephelometer Analyzer System (Behring Diag-
nostics, Inc, Somerville, NJ) [19]. Coefficients of variation ranged from 3.2% to 16.0% through-
out data collection. Tests were repeated for specimens with results of> 10 mg/L. Because levels
of CRP below 2.2 mg/L were undetectable in the NHANES III, we used clinical cut-offs as pre-
viously described [20]: undetectable (<2.2 mg/L), intermediate (2.2–10 mg/L) and clinically
raised ( 10 mg/L). Differential WBC were measured with automated Coulter Counter
S-PLUS JR Hematology Analyzer (Coulter Electronics, Hialeah, FL) [19]. The maximum coef-
ficients of variation were 5% for absolute granulocyte count and 5% for absolute lymphocyte
count. The G/L ratio was calculated as a ratio of absolute granulocyte to lymphocyte count.
Covariates
Information on age, race/ethnicity, cigarette smoking, alcohol consumption, physical activity,
aspirin use, BCa risk factors, history of diabetes, cardiovascular disease and cancer was col-
lected during the interview. Race and ethnicity were combined into four racial/ethnic groups:
non-Hispanic white, non-Hispanic black, Mexican American, and other. Participants were
classified as never, former, and current smokers (< 20, 20–40, 40 cigarettes per day), based
on the self-reported smoking habits. Frequency of alcohol consumption was measured by a
food frequency questionnaire and categorised by times per week. Vigorous physical activity
(yes, no) was defined as participating three or more times per week in the following activities:
jogging or running; swimming or aerobics (age<65 years); biking, dancing, gardening, and
calisthenics (65 years); and walking and lifting weights (80 years). Aspirin use (yes, no) was
assessed based on responses to the question “How often did you take aspirin during the past
month?”. Collected information on BCa risk factors included self-reported menopausal status,
parity, age of menarche, age at first childbirth, history of breastfeeding, use of contraceptive
pills and hormone replacement therapy. Menopausal status was assessed by the following self-
reported criteria: premenopause: last period was 12 and postmenopause: last period>12
months. Women with bilateral oophorectomy and/or hysterectomy were included in the men-
opause group. Parity was grouped based on the number of live births: 0, 1, and 2 or more. His-
tory of breastfeeding was self-reported among parous women. Body measurements were taken
during the examination [17] which included body mass index (BMI) calculated from partici-
pants weight and height, and waist circumference.
Outcomes
The main outcome of the present study was BCa death, however, we also collected data for all-
cause mortality as well as cardiovascular and cancer-specific death as competing outcomes.
Underlying cause of death was based on ICD-9 codes through 1998 and on ICD-10 codes for
deaths occurring after 1998. In order to adjust for changes between the two coding systems,
final cause of deaths occurring prior to 1999 were re-coded into comparable ICD-10-based
underlying cause of death groups [18]. Follow-up time was calculated from interview date/
examination date until date of death or end of study (31 December, 2006), whichever came
first [18].
Statistical analysis
Sampling weights for NHANES III were used to account for sampling variability and to adjust
for differential probability of selection of persons [17]. Multivariable Cox proportional hazards
regression was used to assess risk of death by clinical cut-offs of CRP, as well as log-transformed
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values and tertiles of detectable CRP, AGC, and G/L ratio. A test for trend was conducted by
using assignment to categories as an ordinal scale. In the multivariable model, we performed
further adjustment for cigarette smoking, alcohol consumption, vigorous physical activity, use
of aspirin. Additional adjustment for BCa risk factors was performed when assessing BCa
death. Due to the large number of missing data (> 10%) of other risk factors, only menopausal
status, age at menarche and use of contraceptive pills were included in the final analyses, and
missing values for these variables were coded as a separate category and included in the analysis.
To account for potential confounding by obesity [10], we repeated our analyses while adjusting
the models for BMI andWC. Given their potential overlap, we conducted a test for collinearity
with variance inflation factor (VIF) for BMI and waist circumference as predictors of BCa
death. VIF obtained was less than 2, indicating a lack of severe multi-collinearity [21]. There-
fore, we retained both BMI and waist circumference in the model. Sensitivity analyses for BCa
death was performed by excluding those with follow-up time less than 3 years (N = 957).
Finally, to evaluate effect modification, we performed stratified analyses by obesity using BMI
30 kg/m2 as a cut-off and the median of waist circumference. We also performed a test for mul-
tiplicative interaction by including an interaction term between categories of inflammatory
markers and obesity status, categories of waist circumference or menopausal status in the
model. Due to small number of BCa deaths in these stratified analyses, only log-transformed
values and trends from analyses with categories were displayed. Cumulative incidence functions
were created for death from different causes, and for BCa death by clinical cut-offs of CRP and
tertiles of AGC and G/L ratio. We performed Gray’s Test for Equality of Cumulative Incidence
Functions to assess between-groups differences in the presence of competing risks. All analyses
were conducted with SAS release 9.4 (SAS Institute, Cary, NC) and R version 3.1.0 (R Founda-
tion for Statistical Computing, Vienna, Austria).
Results
During a mean follow-up time of 167 months, a total of 1,676 women died: 307 of cancer,
including 44 who died of BCa, and 779 of cardiovascular disease. Baseline characteristics of
study participants are shown in Table 1.
CRP, AGC, G/L ratio and BCa death
When using the clinical cut-off of CRP, we did not observe any statistically significant associa-
tion between CRP and risk of BCa death. However, among those women with detectable CRP
levels, higher CRP was associated with an increased risk of BCa death (HR: 1.82 (95% CI: 1.02–
3.25) for every log increase). We also found continuous AGC to be positively associated with
BCa death (HR: 3.96 (95% CI: 1.10–14.12) for every log increase in AGC), although this was
not observed with tertiles of AGC (Fig 1). A positive association with BCa death was also found
for both the log-transformed G/L ratio as well as the tertiles of G/L (e.g. HR: 4.28 (95% CI:
1.88–9.74) for every log increase in G/L ratio). The results were similar when we excluded
women with less than three years of follow-up (results not shown).
Effects of obesity and menopausal status
When we performed an additional adjustment for BMI, the observed associations between log-
transformed values of detectable CRP and AGC with BCa death disappeared (results not
shown). Lack of associations were also found when using CRP cut-offs and AGC tertiles (Fig 1),
whereas G/L ratio remained statistically significantly associated with risk of BCa death (e.g HR:
2.35 (95% CI: 1.36–4.06) for the highest compared to lowest tertile of G/L ratio in the BMI-
adjusted model; Ptrend = 0.01). Findings were similar in the sensitivity analyses. For instance, the
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Table 1. Characteristics of study participants by status at the end of follow-up.
Weighted mean (SD)/ N (weighted %)
Breast cancer death
(n = 44)
All cancer death
(n = 307)
Cardiovascular death
(n = 779)
All death
(n = 1,676)
Alive
(n = 6,104)
Age (years)
Mean (SD) 48.93 (3.83) 60.13 (1.41) 71.87 (0.86) 67.60 (0.74) 40.81 (0.43)
Mean follow-up (months)
Mean (SD) 110.57 (11.12) 101.62 (4.40) 97.42 (2.37) 101.67 (1.95) 179.65 (2.88)
Race—Ethnicity
Non-Hispanic white 16 (71.45) 163 (81.99) 480 (83.97) 978 (82.26) 2255 (74.60)
Non-Hispanic black 17 (14.91) 84 (11.34) 165 (10.66) 389 (11.21) 1792 (11.29)
Mexican American 9 (3.26) 51 (2.53) 113 (2.11) 261 (2.34) 1758 (5.26)
Other 2 (10.38) 9 (4.13) 21 (3.27) 48 (4.19) 299 (8.85)
Alcohol consumption
Never 28 (57.90) 205 (62.20) 641 (75.67) 1312 (71.51) 3603 (49.70)
Up to 6 times a week 10 (29.97) 77 (19.85) 107 (13.01) 280 (14.47) 2257 (22.24)
Daily or more 6 (12.12) 25 (7.79) 31 (6.71) 84 (6.69) 244 (5.14)
Cigarette smoking
Never 23 (58.84) 140 (38.05) 515 (58.36) 1001 (50.29) 3825 (56.31)
Former 5 (10.31) 70 (27.61) 165 (23.97) 362 (25.43) 949 (18.60)
Current 16 (30.85) 97 (34.34) 99 (17.67) 313 (24.28) 1330 (25.09)
Vigorous Physical activity 3 (11.70) 53 (19.83) 179 (27.40) 353 (24.00) 367 (6.21)
Waist circumference (cm) 1 99.30 (4.59) 98.93 (1.54) 95.08 (0.88) 94.94 (0.53) 87.61 (0.43)
BMI (kg/m2) 29.66 (1.71) 29.90 (0.88) 27.23 (0.32) 27.39 (0.15) 26.32 (0.20)
Menopausal status2
Premenopause 17 (51.51) 51 (16.88) 35 (5.90) 138 (10.46) 3961 (64.14)
Postmenopause 26 (48.49) 240 (79.28) 628 (92.96) 1347 (87.89) 1974 (29.85)
Age at menarche3 (years)
Mean (SD) 12.94 (0.50) 12.69 (0.11) 13.09 (0.07) 13.00 (0.07) 12.76 (0.04)
Age at ﬁrst childbirth4
(years)
Mean (SD) 22.14 (0.76) 22.50 (0.36) 22.77 (0.22) 22.65 (0.18) 22.24 (0.13)
History of breastfeeding5 19 (40.24) 157 (58.68) 393 (66.38) 845 (62.01) 394 (53.75)
Parity6
0 3 (12.07) 16 (6.17) 26 (4.53) 53 (3.85) 319 (8.37)
1 6 (17.07) 37 (14.78) 113 (18.47) 223 (16.55) 1001 (20.43)
2+ 29 (70.86) 208 (79.05) 441 (77.00) 1016 (79.60) 3806 (71.20)
History of oral
contraception7
22 (72.90) 86 (39.61) 68 (13.35) 226 (35.10) 3842 (45.92)
Hormone replacement
therapy8
3 (14.62) 71 (41.03) 159 (34.32) 345 (21.28) 844 (78.72)
Aspirin use 17 (46.44) 114 (39.51) 301 (45.32) 608 (40.50) 1759 (33.88)
CRP (mg/L)
Undetectable (< 2.2) 22 (56.9) 177 (57.25) 432 (54.65) 909 (54.75) 3773 (67.98)
Intermediate (2.2–10) 13 (24.22) 84 (25.46) 225 (27.38) 492 (26.91) 1639 (23.43)
Clinically raised ( 10) 9 (18.78) 46 (17.29) 122 (17.97) 275 (18.34) 692 (8.60)
AGC (103 cells/L)
Mean (SE) 5.39 (0.53) 4.82 (0.18) 4.85 (0.09) 4.85 (0.07) 4.56 (0.05)
G/L ratio
(Continued)
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HR for BCa death was 4.02 (95%: 1.64–9.85) for continuous G/L ratio when excluding women
with less than 3 years of follow-up (results not shown in tables). When stratifying by overweight
status and categories of waist circumference, we only observed a positive trend between continu-
ous log-transformed values of G/L ratio and risk of BCa death in women with waist circumfer-
ence above the median (Table 2), with hazard ratios of 7.20 (95% CI: 1.29–40.25). However,
there was no statistically significant interaction between the three markers and obesity status
apart from a borderline interaction between CRP and obesity by BMI (Pinteraction = 0.05). In
another stratified analyses based on menopausal status, no associations were found with BCa
death for premenopausal or postmenopausal women separately. A lack of statistically significant
interaction was also found between all three inflammatory markers and menopausal status when
assessing BCa death (Pinteraction0.05).
Table 1. (Continued)
Weighted mean (SD)/ N (weighted %)
Breast cancer death
(n = 44)
All cancer death
(n = 307)
Cardiovascular death
(n = 779)
All death
(n = 1,676)
Alive
(n = 6,104)
Mean (SE) 2.61 (0.27) 2.29 (0.11) 2.45 (0.05) 2.38 (0.04) 2.11 (0.03)
Information available in 17618, 27420, 37285, 46031, 56044, 66418, 77410 and 83422 women.
doi:10.1371/journal.pone.0157482.t001
Fig 1. Hazard ratios (HR) and 95% confidence intervals (95%CI) for risk of death from BCa, overall cancer, cardiovascular disease and all
causes by clinical cut-offs of CRP and tertiles of absolute granulocyte count and G/L ratio. All models were adjusted for age, race-ethnicity,
cigarette smoking, alcohol consumption, vigorous physical activity, menopausal status, age of menarche, use of oral contraception and aspirin.
doi:10.1371/journal.pone.0157482.g001
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CRP, AGC, G/L ratio and other causes of death
Only AGC was associated to risk of overall cancer death, e.g. HR: 1.48 (95% CI: 1.01–2.17) for
the 3rd compared to the 1st tertile (Fig 1). The risks of dying from cardiovascular disease and all
causes were consistently higher with increased CRP, AGC and G/L ratio (Fig 1). Interestingly,
no effect modification by obesity status by BMI and waist circumference was observed for the
association between any markers and risk of other causes of death apart from BCa (Table 2).
Table 2. Hazard ratios (HR) and 95% confidence intervals (95%CI) for risk of death due to BCa, overall cancer, cardiovascular disease and all
causes by continuous levels of clinically detectable CRP, absolute granulocyte count and G/L ratio, and trends from categories of markers, strati-
fied by overweight status andmedianWC. All models were adjusted for age, race-ethnicity, cigarette smoking, alcohol consumption, vigorous physical
activity, menopausal status, age of menarche, use of oral contraception and aspirin.
N CRP (mg/L) AGC (103/L) G/L ratio
HR (95% CI) per
log increase1
Ptremd
2 Pinteraction HR (95% CI)
per log
increase
Ptremd
2 Pinteraction HR (95% CI)
per log
increase
Ptremd
2 Pinteraction
Stratiﬁcation by BMI (kg/m2)
BMI < 30
(N = 5462)
Breast cancer
death
21 1.94 (0.51–7.29) 0.39 5.48 (0.45–
66.27)
0.52 6.51 (0.94–
20.03)
0.38
All cancer death 208 1.13 (0.76–1.67) 0.27 1.63 (1.01–2.63) 0.03 1.11 (0.68–1.80) 0.24
Cardiovascular
death
569 1.45 (1.15–1.82) 0.12 2.22 (1.39–3.56) 0.007 1.99 (1.49–2.65) 0.003
All death 1207 1.49 (1.27–1.76) 0.002 2.00 (1.52–2.66) <0.0001 1.62 (1.32–2.00) <0.0001
BMI  30
(N = 2318)
Breast cancer
death
23 1.40 (0.52–3.77) 0.76 0.05 2.85 (0.31–
25.92)
0.58 0.73 6.51 (0.97–
43.74)
0.13 0.93
All cancer death 99 1.26 (0.65–2.47) 0.43 0.15 1.97 (0.69–5.61) 0.58 0.59 3.11 (0.87–
11.17)
0.16 0.41
Cardiovascular
death
210 1.29 (0.77–2.17) 0.43 0.79 1.66 (0.73–3.76) 0.51 0.37 1.46 (0.76–2.83) 0.18 0.61
All death 469 1.43 (1.07–1.91) 0.24 0.43 1.89 (1.16–3.08) 0.05 0.53 1.85 (1.12–3.06) 0.02 0.82
Stratiﬁcation by waist circumference (cm)
Waist circumference < 90.10 (N = 3615)
Breast cancer
death
11 2.30 (0.39–13.43) 0.78 1.01 (0.12–9.56) 0.82 1.51 (0.25–9.10) 0.86
All cancer death 108 0.88 (0.37–2.10) 0.93 1.38 (0.70–2.69) 0.25 1.37 (0.70–2.69) 0.50
Cardiovascular
death
230 2.36 (1.64–3.40) 0.003 2.07 (1.06–4.03) 0.03 1.96 (1.24–3.08) 0.05
All death 514 1.72 (1.26–2.36) 0.03 1.60 (1.12–2.30) 0.01 1.48 (1.15–1.91) 0.03
Waist circumference  90.10 (N = 4003)
Breast cancer
death
33 1.81 (0.98–3.35) 0.41 0.22 5.16 (0.59–
44.96)
0.32 0.55 7.20 (1.29–
40.25)
0.07 0.29
All cancer death 190 1.22 (0.74–2.02) 0.25 0.67 1.70 (0.86–3.35) 0.30 0.97 1.51 (0.60–3.77) 0.21 0.79
Cardiovascular
death
465 1.20 (0.82–1.76) 0.07 0.11 2.06 (1.35–3.15) 0.81 0.90 1.85 (1.28–2.66) 0.004 0.96
All death 1030 1.40 (1.15–1.68) 0.007 0.49 2.13 (1.59–2.86) 0.77 0.69 1.82 (1.32–2.51) 0.0003 0.30
1 Clinically detectable levels of CRP were used as a continuous variable ( 2.2 mg/L)
2 Ptrend from regression models using clinical categories of CRP and tertiles of AGC and G/L ratio
doi:10.1371/journal.pone.0157482.t002
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Fig 2 shows the distribution of cumulative mortality from BCa, other cancer, cardiovascular
disease and other causes for women in the highest and lowest categories of CRP, AGC, and
G/L ratio. When accounting for other causes of death as competing risks, we found higher BCa
mortality rates over time in women in the top CRP and GLR categories compared to the lowest,
but no statistically significance difference was observed (Gray’s test: P0.05). Similar but
stronger associations for the three inflammatory markers were found for cardiovascular death
(Fig 2).
Fig 2. Cumulative mortality from BCa, other cancer and cardiovascular disease by the highest and lowest categories of CRP, AGC and G/L
ratio.Gray’s test for equality of cumulative incidence functions was performed in presence of competing risks.
doi:10.1371/journal.pone.0157482.g002
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Discussion
In the present study, the G/L ratio was shown to be linked to BCa death even after taking into
account adiposity. Although a borderline interaction between CRP and obesity by BMI was
observed, no statistically significant interaction between any inflammatory markers and obesity
status or menopausal status was found. Additionally, levels of CRP, AGC and G/L ratio were
statistically significantly associated with risk of cardiovascular and all-cause death. No associa-
tion was observed between the studied inflammatory markers and risk of all-cancer death after
obesity was taken into account.
Observations of leukocytes infiltration in tumour tissue were among the earliest evidence
indicating a link between inflammation and cancer [22]. The inflammatory milieu has been
recognised as an important part of cancer microenvironment, but in contrast to typical inflam-
matory responses, it is characterized by defective immune effectors including alternatively-acti-
vated macrophages [23], dysfunctional dendritic cells (DC) [24], mast cells [25] and
lymphocytes [26]. It is thought that these impaired immune responses in cancer are driven by
a subpopulation of myeloid-derived cells with immunosuppressive properties, comprising
macrophages, granulocytes, and DCs at varying stages of differentiation and expressing specific
markers including CD11b and Gr-1 [27]. Corroborating this hypothesis, a suppression of cyto-
toxic T cells activity by CD11b+ granulocytes and macrophages in animal models of cancer has
been reported [28], which is thought to underlie the immune tolerance to cancer. Correspond-
ingly, infiltrates of T cells triggered by tumour-associated antigens are linked to better survival
in cancer patients [29], whereas tumour-associated macrophages have been associated to
metastasis and worse prognosis [30].
How systemic inflammation fits into this relationship between inflammation and cancer
remains elusive, since tumour-infiltrating immune cells harbour different characteristics from
their equivalents in circulation [22]. Nevertheless, similar to contrasting effects between infil-
trates of granulocytes and lymphocytes, circulating granulocytes have been reported to inhibit
the cytotoxic effect of lymphocytes [31], implying the potential usefulness of systemic inflam-
matory markers in relation to cancer. However, underlying factors such as obesity [32] and
infection [33] might be triggers of activation of these immune cells and cancer initiation.
In the context of prognosis, increased pre-treatment CRP levels in BCa patients have been
linked with decreased progression-free and overall survival, with a hazard ratio for disease pro-
gression of 1.65 (95% CI: 1.26–2.15) for women in the highest tertile of CRP compared to the
lowest [34]. The association between CRP and risk of being diagnosed with BCa is less clear
[9,35]. In 9,605 women included in the Copenhagen City Heart Study [36], no association was
reported between baseline CRP and risk of developing BCa (HR: 0.70 (95% CI, 0.40 to 1.40) for
CRP more than 3 versus less than 1 mg/L) when adjusting for lifestyle factors including BMI. A
lack of association between CRP and BCa incidence was also reported in a recent study of
155,179 Swedish women [37]. In contrast, a nested case-control study in France showed a posi-
tive association between CRP and postmenopausal BCa among overweight and obese women
or those with waist circumference 80 cm, with a significant interaction between CRP and
BMI [38]. Similar to the null finding in the Danish study [36], we found lack of associations
between CRP and risk of BCa death after adjustment for BMI and waist circumference. It is of
note, however, that we did not have information on BCa incidence. Therefore, the use of BCa
death as a surrogate endpoint may have underestimated the association between inflammatory
markers and BCa and is not fully comparable to findings from studies where diagnosis of BCa
is available. With respect to adiposity, a positive association between clinically detectable CRP
(2.2 mg/L) and risk of BCa death was observed for overweight and obese women and those
with waist circumference above median. Nevertheless, no statistically significant interaction
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was found, although a borderline interaction was found with obesity as defined by BMI. There-
fore, our findings did not support any major effect of adiposity on the association between
CRP and BCa death. =
Neutrophils are the most abundant granulocytes in the circulation [16], and ANC is rou-
tinely used as marker in monitoring chemotherapy-induced myelosuppression [39]. With
regards to BCa diagnosis, however, there is a lack of evidence assessing the potential signifi-
cance of this marker. In the present study, we found no association between AGC and risk of
BCa death after adjustment for BMI. No participants reported a history of cancer diagnosis at
baseline, so that alterations of neutrophil levels by cancer or its treatment were unlikely to
affect the results of this study.
Similar to NLR [40], a high G/L ratio has been reported to be linked to worse prognosis in
colorectal cancer in studies on cancer prognosis [41], but its importance in relation to BCa inci-
dence is not widely investigated yet. In our study, the G/L ratio was a strong predictor of BCa
death and unlike AGC and CRP, it was not affected by BMI and waist circumference adjust-
ments. Furthermore, this association was robust after exclusion of women with less than three
years of follow up. In the stratified analysis, there was a weak indication that the link between
the G/L ratio and BCa death was affected by menopausal status, but the small sample size may
have driven the lack of statistical power. Stratification by overweight status showed a stronger
associations between G/L ratio and BCa death in overweight and obese women and those with
waist circumference above median, which may support the proposed obesity-inflammation-
cancer axis in breast carcinogenesis [42]. Nevertheless, the lack of significant interaction may
point towards the importance of alternative inflammatory pathways.
Finally, the strong association between markers of inflammation and death from cardiovas-
cular disease and all causes highlight the importance of competing risks when analysing
inflammatory markers in relation to time to cancer death. Cardiovascular disease is the most
frequent cause of death [43] and may result in a competing risk situation when assessing BCa
death. Cumulative mortality rates of cardiovascular death were markedly higher in women
with elevated levels of CRP, AGC, and G/L ratio. Therefore, any woman with high baseline lev-
els of inflammatory markers who are at risk of dying from BCa was more likely to die first
from cardiovascular disease before experiencing fatal BCa [44], and this may explain the
weaker effects of serum CRP and G/L ratio on cumulative mortality from BCa. However, we
observed similar but non-significant trends of CRP and G/L ratio with cumulative BCa death
after taking competing risk into account.
The strength of this study is its generalisability following the use of nationally representative
data of the US population. We were able to adjust for potential confounders and stratify by
overweight and menopausal status in women. A limitation of this study is that it relied on a sin-
gle measurement, so that it may be prone to measurement error and within-person variation.
As inflammation arises following cancer [1], effects of reverse causation may remain even after
excluding those with< 3 years of follow-up. Additionally, the laboratory methods used for
CRP measurement at the time the NHANES III was conducted were unable to perform a high
sensitivity assay of this marker. Nevertheless, serum CRP in the NHANES III population was
reported to be associated to CRP-related genetic variation [45], justifying the usefulness of this
marker despite its limitation in detecting low levels of CRP. In stratification analyses, we only
used continuous values of markers given the small number of events, and for CRP, this
excluded half (50%) of BCa cases with undetectable levels. This exclusion may limit the gener-
alisability to our findings for this particular analysis to those with mild to clinically evident sys-
temic inflammation. The small number of BCa deaths was also a major limitation of our study
and may have resulted in imprecision. Additionally, no history of breast cancer diagnosis was
available. Finally, BCa is a disease with high survivorship. Using BCa mortality due to a lack of
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information on cancer incidence in our study may have underestimated the association
between inflammation and BCa. Consequently, our results may have implied a role of inflam-
mation in more severe BCa, which may be represented by women dying specifically from BCa.
Further investigations including cancer incidence and prognostic indicators are needed to clar-
ify this association.
Conclusion
Our findings support a role of inflammation in breast cancer. Although we found, the associa-
tion between serum inflammatory markers and BCa to be more profound with excess adipos-
ity, no statistically significant interaction between any of the three inflammatory markers
investigated and BMI or waist circumference as indicators of obesity. This may imply alteran
the need for future mechanistic studies investigating underlying biological pathways linking
inflammation and breast cancer beyond obesity. Additionally, we demonstrated that the G/L
ratio, an alternative marker for inflammation, may be useful in assessing risk of BCa mortality
in women without known history of cancer. However, weaker associations were observed in
presence of competing risks, and therefore addressing other causes of death is important in
assessing inflammatory markers in relation to BCa death.
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